PHM Protech Home Medical Corp

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE
SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN.


Patient Home Monitoring Corp. (TSX VENTURE:PHM) ("PHM") announced it has
executed Letters of Intent (LOIs) to acquire two additional companies servicing
patients with chronic illnesses. Based upon their trailing 12-month earnings,
the acquisition of these growing and profitable companies will be immediately
accretive to the income statement and will substantially increase PHM's
earnings-per-share (EPS). PHM also released an updated investor presentation. 


PHM has agreed to pay a price of less than four times 2013 Adjusted EBITDA. The
majority of the purchase price will be paid in PHM common shares with the
remainder in cash. The owners of the businesses have agreed to exchange
ownership in their company for PHM shares priced at $0.27 per share. The key
executives of both companies have agreed to join PHM in senior management roles
to continue to grow the companies, as well as to assist in growing other
elements of PHM's business. PHM can close both acquisition opportunities with
cash-on-hand from its current balance sheet and plans to issue additional shares
as part of the acquisitions. Because the sellers have agreed to a $0.27 share
value, shares issued as part of the acquisition are estimated to be less than
10% of the total common shares outstanding. PHM plans to assume a small amount
of debt as part of the acquisition price. Closing the acquisitions will be
subject to final due diligence and purchase agreements and TSX Venture Exchange
review and approval.


When these companies are added to PHM's current operations, the expected
financial results of all entities combined 12-month trailing Adjusted EBITDA
will be an increase of over 400% in EBITDA growth from the prior reported
quarter or in excess of $3,000,000(i) subject to final due diligence. In
addition, the cross-selling potential is expected to further drive EBITDA
growth.


The companies are located in the southeastern United States and service patients
with chronic pulmonary disease. They are established companies that have been
profitable for many years, and are well positioned to thrive in the changing
reimbursement environment. The acquisitions would give PHM additional service
lines to increase organic growth through cross-selling opportunities with PHM's
existing cardiology services and pulmonology drug distribution services.
Combined, these businesses service thousands of patients with multiple chronic
illnesses that may benefit specifically from PHM's Coumadin testing services and
pulmonology drug distribution services. 


The updated investor presentation can be found at
http://phmhometesting.com/investor/public/dl/PHM%20Presentation%20-%20Nov%202013.pdf.


"With these acquisitions, PHM's services will now cover drug delivery, essential
medical equipment, home monitoring and clinical support services, making us a
more complete patient home service business. The result will be healthier
patients, lower costs and improved healthcare delivery," said Bob Kusher, CEO of
PHM. "We expect strong revenue growth in our service lines to continue as health
care providers scale back budgets and are being forced out of providing niche,
high value added products and services. I believe the willingness of the key
executives who have built these businesses over the course of a decade to take a
majority of their payment in PHM common shares is a testament to the opportunity
they see in PHM and the transaction structure is advantageous to existing PHM
shareholders." 


"We are excited to move to the next stage with the acquisition targets,"
continued Mr. Kusher. "I view this transaction both as an earning accretive deal
and an acquisition of talent, as the key executives who have built these
businesses over the course of a decade see the opportunity to join forces with
PHM as the way to grow revenues and profitability. Their willingness to take a
majority of their payment in stock is a testament to the opportunity both they
and I see in PHM. The future executives will realize an increased value from
this transaction by growing the PHM share price from their starting point of 27
cents. Best of all, this transaction structure aligns incentives for all PHM
shareholders."


About PHM

The explosive growth in the number of elderly patients in the US healthcare
market is creating pressure to provide more efficient delivery systems.
Healthcare providers, such as hospitals, physicians and pharmacies, are seeking
partners that can offer a range of products and services that improve outcomes,
reduce hospital readmissions, and help control costs.PHM fills this need by
delivering a growing number of specialized products and services to achieve
these goals.


(i) These Adjusted EBITDA figures are unaudited and may change subject to due
diligence and closing procedures. They are intended only as an estimate of
trailing twelve month Adjusted EBITDA of the combined entities and are not meant
to convey forward looking information. Adjusted EBITDA is a Non-IFRS measure the
Company uses as an indicator of financial health, and excludes several items
which may be useful in the consideration of the financial condition of the
Company, including interest expense, taxes, depreciation, amortization, stock
based compensation, and owner compensation.


Information in this news release that is not current or historical factual
information may constitute forward-looking information within the meaning of
securities laws. Implicit in this information, particularly in respect of the
future outlook of PHM and anticipated events or results, are assumptions based
on beliefs of PHM's senior management as well as information currently available
to it. While these assumptions were considered reasonable by PHM at the time of
preparation, they may prove to be incorrect. Readers are cautioned that actual
results are subject to a number of risks and uncertainties, including the
availability of funds and resources to pursue operations, decline of
reimbursement rates, dependence on few payors, possible new drug discoveries, a
novel business model, dependence on key suppliers, granting of permits and
licenses in a highly regulated business, competition, low profit market segments
as well as general economic, market and business conditions, and could differ
materially from what is currently expected.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


This press release does not constitute and the subject matter hereof is not, an
offer for sale or a solicitation of an offer to buy, in the United States or to
any "U.S. Person" (as such term is defined in Regulation S under the U.S.
Securities Act of 1933, as amended (the "1933 Act")) of any equity or other
securities of PHM. The securities of PHM have not been registered under the 1933
Act and may not be offered or sold in the United States (or to a U.S. Person)
absent registration under the 1933 Act or an applicable exemption from the
registration requirements of the 1933 Act.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Patient Home Monitoring Corp.
Michael Dalsin
Chairman
(323) 253-3055

Patient Home Monitoring Corp. (TSXV:PHM)
Historical Stock Chart
From Sep 2024 to Oct 2024

Patient Home Monitoring Corp. (TSXV:PHM)
Historical Stock Chart
From Oct 2023 to Oct 2024